<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02757534</url>
  </required_header>
  <id_info>
    <org_study_id>201504713</org_study_id>
    <nct_id>NCT02757534</nct_id>
  </id_info>
  <brief_title>Domperidone for Chronic Nausea and Vomiting</brief_title>
  <official_title>Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yehudith Assouline-Dayan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide oral domperidone to patients with gastroparesis,
      between the ages of 18 and 60 years of age, who have failed standard treatment. Standard
      therapy at the University of Iowa is eating blended foods, liquid diet, Eryped syrup (125 mg
      TID) 30 minutes before meals, or reglan (20 mg BID).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of symptoms for patients with gastroparesis who have failed standard medical treatment</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>1 week after beginning study drug treatment</time_frame>
    <description>Analyze QT value per PI judgement</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Domperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug that all subjects will receive is Domperidone. Subjects will take 10 mg of the drug, up to four times a day for a dosage maximum of 40 mg. Duration of treatment period will depend on subject, they may take the drug for as long as they are able to tolerate it.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Domperidone</intervention_name>
    <description>The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.</description>
    <arm_group_label>Domperidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female

          2. Age 18 - 60

          3. Symptoms or manifestation secondary to gastroparesis such as vomiting, nausea, the
             feeling you are full after you start eating, bloating and abdominal pain.

          4. Subjects must have a comprehensive evaluation to eliminate other causes of their
             symptoms which includes gastric emptying scintigraphy, esophagogastroduodenoscopy
             (EGD), and the patient's subjective symptoms.

          5. Subject has signed informed consent for the administration of domperidone that informs
             the patient of potential adverse events including:

               -  increased prolactin levels

               -  extrapyramidal side effects

               -  breast changes

               -  cardiac arrhythmias including QT prolongation and death

          6. Female subjects must be:

               -  surgically sterile (have had a hysterectomy or bilateral oophorectomy, or tubal
                  ligation)

               -  if sexual active, practicing an effective method of birth control such as
                  hormonal prescription oral contraceptives, progesterone implants or injections,
                  contraceptive patch, intrauterine device, or maintenance of a monogamous
                  relationship with a male partner who has been surgically sterilized by vasectomy.
                  A double barrier method such as condoms, diaphragms, or cervical caps with
                  spermicidal foam, cream, or gel may be used as a method of birth control

        Exclusion Criteria:

          1. History of, or current, arrhythmias including ventricular tachycardia, ventricular
             fibrillation, atrial fibrilation and Torsade des Pointes, subjects with minor forms of
             ectopy (PACs) are not necessarily excluded

          2. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged
             corrected QT interval (QTc) (QTc&gt;450 milliseconds for males, QTc&gt;470 milliseconds for
             females)

          3. Clinically significant electrolyte disorders

          4. Hepatic dysfunction

          5. Renal insufficiency

          6. Gastrointestinal hemorrhage or obstruction

          7. Presence of a prolactinoma (prolactin-releasing pituitary tumor)

          8. Pregnant or breast feeding female

          9. Known allergy to domperidone

        The following medications are prohibited during the study:

          1. Antidepressants: doxepin (Adapin®, Sinequan®, Zonalon®), clomipramine (Anafranil®),
             amoxapine (Asendin®), trazodone (Desyrel®), venlafaxine (Effexor®), nefazodone
             (Serzone®), fluvoxamine (Luvox®), paroxetine (Paxil®), fluoxetine (Prozac®, Sarafem®),
             nefazodone (Serzone®), sertraline (Zoloft®), amitriptyline (Elavil®, Endep®, Etrafon®,
             Limbitrol®, Triavil®), maprotiline (Ludiomil®), desipramine (Norpramin®),
             nortriptyline (Pamelor®), trimipramine (Surmontil®), imipramine (Tofranil®),
             protriptyline (Vivactil®),

          2. Anti-psychotics: haloperidol (Haldol®), chlorpromazine (Thorazine®, Ormazine®),
             chlorpromazine pimozide (Orap®), sertindole (Serlect®), quetiapine (Seroquel®),
             mesoridazine (Serentil®), perphenazine (Triavil®), fluphenazine (Apo-Fluphenazine®,
             Modecate Concentrate®, Moditen®, Permitil®, phenazine methosulfate-Fluphenazine®,
             Prolixin®, Rho-Fluphenazine®), promazine (Sparine®), trifluoperazine (Stelazine®)

          3. Anti-Emetics: prochlorperazine (Compazine®), thioridazine (Mellaril®), promethazine
             (Phenergan®), mesoridazine (Serentil®), thiethylperazine, (Torecan®), perphenazine
             (Trilafon®), dolasetron (Anzemet®), dronabinol (Marinol®), droperidol (Inapsine®)

          4. Anti-infective agents: erythromycin (such as E.E.S.®, E-Mycin®, Ilotycin® ,
             Pediazole®, Akne-mycin®), clarithromycin (Biaxin®), troleandomycin (TAO®), norfloxacin
             (Ciproxin®, Noroxin®), quinine sulfate, quinupristin and dalfopristin (Synercid®),
             pentamidine (Nebupent®, Pentacarinat®, Pentam®), sparfloxacin (Zagam®), grepafloxacin
             (Raxar®), azithromycin (Zithromax®), ofloxacin (Floxin®). Levofloxacin (Levaquin®)

          5. Anti-Fungal Agents: fluconazole (Diflucan®), itraconazole (Sporanox®), ketoconazole
             (Nizoral®), miconazole (Micatin®, Monistat®), terconazole (Terazol®), tioconazole
             (Vagistat®), butoconazole (Femstat 3®)

          6. Antivirals: foscarnet (Foscavir®)

          7. Protease Inhibitors: indinavir (Crixivan®), amprenavir (Agenerase®), ritonavir
             (Norvir®), nelfinavir (Viracept®), saquinavir (Invirase®, Fortovase®),

          8. Anti-Hypertensives: nicardipine (Cardene®), isradipine (Dynacirc®), moexipril/
             hydrochlorothiazide (HCTZ) (Uniretic®)

          9. Calcium Channel Blockers: verapamil (Calan®), diltiazem (Cardizem®),
             diltiazem/enalapril (Teczem®), verapamil/trandolapril (Tarka®), tocainide (Tonocard®),
             bepridil (Vascor®)

         10. Anti-Arrhythmics: disopyramide (Norpace®, Norpace Controlled Release ®), quinidine
             (such as Quinidex®, Cardioquin®, Quinaglute®, Duraquin®), procainamide (Procanbid® ,
             Procan®, Pronestyl®,), flecainide (Tambocor®), sotalol (Betapace®), bretylium
             (Bretylol®), amiodarone (Cordarone®), ibutilide (Corvert®), moricizine (Ethmozine®)

         11. Diuretics: bumetanide (Bumex®), furosemide (Lasix®), torsemide (Demadex®), ethacrynic
             Acid (Edecrin®), chlorothiazide (Diuril®), Indapamide (Lozol®)

         12. Antilipemics: probucol (Lorelco®), Bepridil (Vascor®), mibefradil (Posicor®),

         13. Hematological Agents: cilostazol (Pletal®)

         14. Respiratory Agents: zafirlukast (Accolate®), salmeterol (Serevent®)

         15. Gastrointestinal Agents: cimetidine (Tagamet®), cisapride (Propulsid®)

         16. Antidiarrheal: octreotide (Sandostatin®)

         17. Antihistamines: azelastine (Astelin®), clemastine (Tavist®)

         18. Migraine treatment: naratriptan (Amerge®), sumatriptan (Imitrex®), zolmitriptan
             (Zomig®)

         19. Antimalarial: halofantrine

         20. Muscle relaxants: tizanidine (Zanaflex®)

         21. Narcotic Dependence: levomethadyl (Orlaam®)

         22. Miscellaneous: tamoxifen (Nolvadex®), warfarin (Coumadin®), phenytoin (Dilantin®),
             ziprasidone (Geodon®), risperidone (Risperdal®), formoterol fumarate (Foradil
             Aerolizer®), sildenafil (Viagra®)

         23. Drugs that prolong the QT Interval: albuterol, alfuzosin, amantadine, amisulpride,
             amphetamine, arsenic trioxide, astemizole, atazanavir, atomoxetine, chloral hydrate,
             chloroquine, ciprofloxacin, citalopram, clozapine, cocaine, dexmethylphenidate,
             diphenhydramine, dobutamine, dofetilide, dopamine, dronedarone, ephedrine,
             epinephrine, eribulin, escitalopram, famotidine, felbamate, fenfluramine, fingolimod,
             fosphenytoin, galantamine, gatifloxacin, gemifloxacin, granisetron, iloperidone,
             isoproterenol, lapatinib, levalbuterol, lisdexamfetamine, lithium, metaproterenol,
             methadone, methylphenidate, midodrine, moxifloxacin, nilotinib, norepinephrine,
             ondansetron, oxytocin, paliperidone, perflutren lipid microspheres, phentermine,
             phenylephrine, phenylpropanolamine, protriptyline, pseudoephedrine, ranolazine,
             ritodrine, roxithromycin, sibutramine, solifenacin, sunitinib, tacrolimus,
             telithromycin, terbutaline, terfenadine, tolterodine, trimethoprim-sulfa, vandetanib,
             vardenafil, voriconazole.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yehudith Assouline-Dayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Yehudith Assouline-Dayan</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

